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The diterpene lactones of Ginkgo biloba, ginkgolides A, B and C are antagonists at a range of Cys-loop
receptors. This study examined the effects of the ginkgolides at recombinant human r1 GABAC recep-
tors expressed in Xenopus oocytes using two-electrode voltage clamp. The ginkgolides were moderately
potent antagonists with IC50s in the mM range. At 10 mM, 30 mM and 100 mM, the ginkgolides caused
rightward shifts of GABA doseeresponse curves and reduced maximal GABA responses, characteristic of
noncompetitive antagonists, while the potencies showed a clear dependence on GABA concentration,
indicating apparent competitive antagonism. This suggests that the ginkgolides exert a mixed-type
antagonism at the r1 GABAC receptors. The ginkgolides did not exhibit any obvious use-dependent
inhibition. Fitting of the data to a number of kinetic schemes suggests an allosteric inhibition as
a possible mechanism of action of the ginkgolides which accounts for their inhibition of the responses
without channel block or use-dependent inhibition. Kinetic modelling predicts that the ginkgolides
exhibit saturation of antagonism at high concentrations of GABA, but this was only partially observed for
ginkgolide B. It also suggests that there may be different binding sites in the closed and open states of the
receptor, with a higher afﬁnity for the receptor in the closed state.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Ginkgolides A, B and C (GA, GB and GC; Fig. 1) are diterpene
lactones and, along with the sesquiterpene lactone bilobalide
(Fig. 1), are found in the leaves of the Ginkgo biloba tree. The extract
of G. biloba leaves has been used for treatments of cerebral and
peripheral vascular dysfunctions and neurosensory disorders
(Blumenthal et al., 2000). Generally, the Ginkgo leaf extract is
standardized to contain 5e7% terpene lactones, consisting of
2.8e3.4% ginkgolides A, B and C, and 2.6e3.2% bilobalide
(Blumenthal et al., 2000).With their oxygenated cage-like structure
and a lipophilic side chain, bilobalide and ginkgolides bear5-HT, 5-hydroxytryptamine/
de A; GB, ginkgolide B; GC,
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uke).
Y license.structural resemblance to the chloride channel blocker picrotoxinin
(PTX, Fig. 1) and they also block GABAA and insect GABARDL
receptors and glycine receptors in a similar manner to PTX (Ivic
et al., 2003; Huang et al., 2003, 2004; Hawthorne et al., 2006;
Heads et al., 2008; Jensen et al., 2010; Thompson et al., 2012). At
lower potency, PTX also blocks the nicotinic acetylcholine (nACh)
and 5-hydroxytryptamine (type 3, 5-HT3) 5-HT3 receptors (Erkkila
et al., 2004; Das and Dillon, 2005; Thompson et al., 2011). There is
evidence that the binding sites of ginkgolides, bilobalide and PTX
are similarly located to that of PTX at glycine, GABARDL, and 5-HT3
receptors (Hawthorne et al., 2006; Heads et al., 2008; Thompson
et al., 2011, 2012).
GABAA, GABAr (GABAC) and GABARDL and glycine receptors are
anion-selective, and nACh and 5-HT3 receptors are cation-selective
members of the Cys-loop receptor superfamily. Receptors in this
superfamily mediate fast synaptic transmission and are appropri-
ately located in the CNS to perform speciﬁc functions. GABAA
receptors are present in all CNS regions (Olsen and Sieghart, 2009)
and GABAC receptors largely in the retina (Qian and Ripps, 2009).
Glycine receptors are mainly found in the brain stem and spinal
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Fig. 1. Structures of ginkgolides A, B and C (GA, GB and GC) (20 carbon atoms), bilobalide (15 carbon atoms) and picrotoxinin (PTX) (15 carbon atoms). These compounds have
cavity-like structures made up of a highly oxygenated carbon skeleton, including two lactone rings and an epoxy group in PTX, and three lactone rings in bilobalide and ginkgolides.
The lipophilic side chain (isopropenyl group in PTX and t-butyl group in bilobalide and ginkgolides) is attached to the underside of the cavity. Ginkgolides A, B and C have two
common hydroxyl groups at C3 and C10 as shown in ginkgolide A. The hydroxyl group at C10 is located at the top and the C3 hydroxyl underneath the main cage comprising rings F,
A, D and C. Two additional rings E and B project outward from the main cage. The C3 hydroxyl of the ginkgolides is next to the polar lactone ring E whereas the only hydroxyl group
in PTX is located at the nonpolar underside of the cage. Note that ginkgolide A lacks the hydroxyl at C1 which acts as an H-bond donor to the C10 hydroxyl in ginkgolides B and C.
The C7 in ginkgolide C projects upwards to the oxolane ring D.
S.H. Huang et al. / Neuropharmacology 63 (2012) 1127e11391128cord (Yevenes and Zielhofer, 2011). GABARDL receptors are found in
the invertebrate brain (Ffrench-Constant et al., 1993).
The receptors in the Cys-loop superfamily have a pentameric
arrangement of subunits forming a central ion-conducting pore.
Eachof the subunits hasa largeextracellularN-terminal domain that
contributes to the agonist binding site and a very short extracellular
C-terminus. TheN- andC-termini are connected by four consecutive
helical transmembrane domains (M1eM4) of which M2 lines the
channel pore (Miyazawa et al., 2003). The opening of the channel
involves movement of the M2 domains. The intracellular loop link-
ingM1 toM2 (M1eM2 linker) is important for ion selectivity and an
extracellular loop linking M2 to M3 (M2eM3 linker) is critical for
signal transduction of agonist binding to theM2 domain for channel
opening (Barry and Lynch, 2005; Miller and Smart, 2010).
The GABAC receptor is composed of r subunits of which three
(r1er3) have been cloned from mammalian retinal cDNA libraries.
The different r subunits are able to form homooligomeric receptors
or heterooligomeric receptors when expressed in Xenopus oocytes.
Co-expression of the r subunit with the GABAA g subunit forms
a receptor with functional properties closely similar to a GABAC
receptor in retinal bipolar cells (Feigenspan and Bormann, 1994,
2006; Qian and Ripps, 2009). The major GABAA receptors are het-
erooligomeric 2:2:1 assemblies of different isoforms and splice
variants of the a, b, g subunit (Olsen and Sieghart, 2009), whereas
the invertebrate GABARDL receptor is a homooligomeric assembly of
the RDL subunit (Ffrench-Constant et al., 1993). The glycine
receptors are homooligomeric assemblies of different isoforms of
the a subunits or heterooligomeric assemblies the a and b subunits
(Yevenes and Zielhofer, 2011).
The subunits of the Cys-loop receptors have high amino acid
sequence homology in the M2 domains. The degree of homology is
greater when considering just the anion- or cation-selective
receptor subunits and greater again for each receptor subtype.
The M2 residues are numbered from 00 to 200 denoting the intra-
cellular to extracellular positions. The M2 residues in the subunits
are generally highly conserved with the exception of the residue at
position 20. In the GABAC receptors, this residue is proline in the r1
subunit, and serine in the r2 and r3 subunits. The r2 subunit has
been shown to confer insensitivity of the GABAC receptors to PTX
(Enz and Bormann, 1995; Zhang et al., 1995; Carland et al., 2008).
The residue 20 of the GABA r subunits inﬂuences the response
kinetics, receptor pharmacology, ion selectivity, and conductance of
GABAC receptors (Zhang et al., 1995; Qian et al., 1999;Wotring et al.,
2003, 2008; Carland et al., 2004a,b,; Filippova et al., 2004; Qian and
Ripps, 2009; Zhu et al., 2007).We have previously shown that ginkgolides A, B and C non-
competitively block GABA-mediated chloride currents with slightly
lower potency to bilobalide and PTX at recombinant human a1b2g2L
GABAA receptors; and bilobalide exhibits mixed-type noncompet-
itive antagonism and use-dependent action similar to PTX at
recombinant human r1 GABAC receptors (Huang et al., 2003, 2004,
2006). Here we extend the study of these cage compounds by
examining the effects of ginkgolides A, B and C on recombinant
human r1 GABAC receptors expressed in Xenopus oocyte.
2. Material and methods
2.1. Materials
Human r1 GABAC receptor subunit cDNA subcloned into pcDNA 1.1 (Invitrogen,
San Diego, CA, USA) was kindly provided by Dr. George Uhl (National Institute for
Drug Abuse, Baltimore, MD, USA). GABA and DMSO were purchased from Sigma
Chemical Co. (St Louis, MO, USA). Ginkgolide A, B and C were isolated from the 50:1
G. biloba leaf extract purchased from Winshing (Australia) Pty Ltd. and puriﬁed by
recrystallization following short column chromatography and. The 1H and 13C NMR
spectra of the puriﬁed picrotoxinin and the ginkgolides were consistent with the
published data (Perry et al., 2001; van Beek, 2005), and also indicated purity>98% in
all cases. Drug solutions were prepared by diluting 100 mM aqueous stock solution
of GABA and either 100mMor 200mMDMSO stock solutions of ginkgolides A, B and
C in ND96 (96 mM NaCl, 2 mM KCl, 1 mMMgCl2$6H2O, 1.8 mM CaCl2, 5 mM HEPES,
pH 7.5). The highest concentration of DMSO superfusing the oocytes was 0.8% at
which concentration DMSO had no effects.
2.2. Expression of r1 GABAC receptors in Xenopus laevis oocytes
Female X. laeviswere anaesthetized with 0.17% ethyl 3-aminobenzoate in saline
and a lobe of the ovaries surgically removed. The lobe of ovaries was rinsed with
a low chloride Ringer’s solution (OR-2 buffer) that contained 82.5 mM NaCl, 2 mM
KCl, 1 mM MgCl2.6H2O, 5 mM HEPES, pH 7.5, and treated with collagenase A (2 mg/
mL in OR-2, Boehringer Mannheim, Germany) for 2 h to separate oocytes from
connective tissues and follicular cells. Released oocytes were then thoroughly rinsed
in ND96 buffer supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophylline
and 50 mg/ml gentamycin, and stage VeVI oocytes were collected.
Human r1 GABAC receptor subunit cDNA was linearized using the restriction
enzyme Xba 1 and transcribed using the “mMESSAGE mMACHINE” kit (Ambion Inc.,
Austin, TX, USA). RNA (10 ng/50 nl) was injected into the cytoplasm of defollicated
oocytes using a 15e20 mm diameter tip glass micropipette Nanoject injector
(Drummond Scientiﬁc Co., Broomali, PA, USA). The oocytes were incubated for 2e7
days at 18 C in ND96 buffer with a twice-daily change of buffer.
2.3. Electrophysiological recording
Whole-cell currents from homomeric r1 GABAC receptors expressed in oocytes
were recorded using two-electrode voltage clamp. Recording microelectrodes were
fabricated with a micropipette puller (Narishige Scientiﬁc Instrument Lab, Tokyo,
Japan) and ﬁlled with 3 M KCl solution. Oocytes were clamped at 60 mV and
continuously superfused with ND96 buffer. The currents elicited in response to the
Table 1
Parameters estimated from the ﬁt of the Hill equation to concentrationeresponse curves in the presence and absence of ginkgolides.
Antagonists (Ant) n GABA EC50 (mM) GABA þ Ant EC50 (mM) GABA nH GABA þ Ant nH Max. GABA response (%)
Ginkgolide A 10 mM 5 1.02  0.05 1.94  0.09 2.03  0.15 1.98  0.12 94.78  0.54*
30 mM 5 0.90  0.05 2.05  0.09 2.29  0.08 2.25  0.04 91.44  0.80y
100 mM 5 1.05  0.15 2.66  0.37 2.09  0.10 2.60  0.22 85.66  1.34*
Ginkgolide B 10 mM 6 1.04  0.10 3.33  0.42 2.03  0.10 1.97  0.10 80.65  2.18*
30 mM 5 0.94  0.03 4.44  0.20 1.97  0.09 1.83  0.06 75.12  1.39*
100 mM 5 1.07  0.08 8.07  0.61 1.68  0.06 1.61  0.05 69.56  2.48y
Ginkgolide C 10 mM 4 1.06  0.06 4.04  0.33 1.86  0.05 1.88  0.05 79.24  2.33*
30 mM 4 1.09  0.04 6.59  0.36 1.81  0.05 1.66  0.05 76.50  2.99y
100 mM 6 0.99  0.05 5.25  0.31 1.38  0.07 1.72  0.03 73.44  2.62*
EC50 is the concentration that evokes a response that is 50% of themaximum, nH is the Hill coefﬁcient and n is the number of data sets. Data are the mean S.E.M. Comparisons
of the maximum responses in the presence and absence of ginkgolide were done by two-way ANOVA. yP < 0.05; *P < 0.01.
Fig. 2. Current traces produced by 1.2 mM GABA (EC50, solid bar) in the presence of
(A) ginkgolide A, (B) ginkgolide B and (C) ginkgolide C at various concentrations from
human r1 GABAC receptors expressed in Xenopus oocytes. The bars indicate duration of
drug application. The ginkgolides did not have any effect on their own when tested at
100 mM.
S.H. Huang et al. / Neuropharmacology 63 (2012) 1127e1139 1129application of GABA were recorded using a GeneClamp 500 ampliﬁer (Axon
Instruments, now Molecular Devices, Sunnyvale, CA, USA), digitized with a Mac Lab
2e recorder (AD Instruments, Sydney, NSW, Australia) and Chart (version 3.5.2)
software (AD Instruments) on a Macintosh Quadra 605 computer. A test dose of
10 mM GABAwas applied to each oocyte to conﬁrm receptor expression prior to the
start of each experiment. For inhibition curves, a range of ginkgolide concentrations
were co-applied with 0.5 mM (wEC15 GABA),1.2 mM (wEC50), 3 mM (wEC80) or 10 mM
(wEC100) test concentrations of GABA in ND96 buffer. Co-applications of ginkgolides
were interleaved with test applications of GABA alone to monitor the response
throughout the experiment. For GABA concentrationeresponse curves, a range of
GABA concentrations (0.01  100 mM) were applied and interleaved with co-
applications in the presence of a ﬁxed concentration of ginkgolide (10 mM, 30 mM
or 100 mM). In this way, a full concentrationeresponse curve was obtained for GABA
in the presence and absence of one concentration of a ginkgolide from each oocyte. A
washout period of 3e5 min was allowed between each application.
2.4. Analysis of data
Analysis and curve ﬁtting was performed using GraphPad Prism v3.02 (Graph-
Pad Software, San Diego, California, USA). Concentrationeresponse curves were
assembled from the peak currents recorded from the range of applied GABA
concentrations, both in the presence and absence of ginkgolides. The data were
expressed as a percentage of the averaged maximum current (Imax) and ﬁtted by
least squares non-linear regression with the empirical Hill equation
I=Imax ¼ ½AnH =

ECnH50 þ ½AnH

where [A] is the agonist concentration, nH is the Hill coefﬁcient and EC50 is the
effective concentration that evoked a 50% of Imax response. Similarly, inhibition
curves were assembled from the peak currents recorded from the range of gink-
golide concentrations applied in the presence of a ﬁxed concentration of GABA. The
data were expressed as a percentage of the peak current (Imax) obtained from the
application of the GABA concentration alone. The concentration that inhibited 50%
of Imax (IC50) was estimated from ﬁtting the data with the Hill equation, where the
concentration of the ginkgolide is substituted for the agonist concentration. Unless
otherwise noted, parameters were calculated from individual oocytes and then
averaged.
The concentrationeresponse curves were ﬁtted with the different mechanisms
of inhibition using a least squares non-linear regression in GraphPad Prism. Each
data set consisting of a control GABA concentrationeresponse curve and three
curves in the presence of ginkgolide (10, 30 and 100 mM) were all ﬁtted simulta-
neously with the same set of parameters. The values for Ka and E were ﬁxed at
3.2 mM and 11, respectively (see Results).
The statistical signiﬁcance of differences between GABA responses with and
without antagonists was determined by two-way ANOVA method, whereas the
differences between IC50 values at different GABA concentrations and the differ-
ences in levels of inhibition between peak and steady-state GABA responses, by
Students t-test at the signiﬁcance level of P < 0.05.
2.5. Homology modelling and docking
Using FUGUE, the protein sequence for the human r1 GABAC receptor subunit
(accession number P24046) was aligned with the GLIC subunit, a bacterial member
of the nAChR superfamily of cationic ion channels activated by protons (PDBID,
3EAM; Shi et al., 2001). GLIC was chosen as it is homomeric, it is reported as being in
the open conﬁguration and it has a higher resolution (2.9 Å) than the nAChR
structure (2BG9). A three-dimensional homology model was generated using
MODELLER 9v8 (Sali and Blundell, 1993) and the best model selected by Ram-
achandran plot using RAMPAGE (Lovell et al., 2003). The three-dimensional struc-
tures of ginkgolide A (GA), ginkgolide B (GB), ginkgolide C (GC) were extracted from
the Cambridge Structural Database (reference codes FUGTOQ01, FATYOO and
UFEHES, respectively) and solvent molecules removed.Rigid ligand docking into the wild type r1 GABAC receptor homology model was
carried out using GOLD 3.0 (The Cambridge Crystallographic Data Centre, Cam-
bridge, UK). The binding site was deﬁned by the Ca atom of T60 on chain A and
constrained to be within 10 Å of the T60 residue of chains A and C (a region that
encompassed the positions between 20 and 90). These amino acids were chosen
based on the binding of similar compounds at other Cys-loop receptors (Enz and
Bormann, 1995; Xu et al., 1995; Zhang et al., 1995; Perret et al., 1999; Zhorov and
Bregestovski, 2000; Das and Dillon, 2005; Hawthorne et al., 2006; Chen et al.,
S.H. Huang et al. / Neuropharmacology 63 (2012) 1127e113911302006; Erkkila et al., 2008; Heads et al., 2008; Jensen et al., 2010; Thompson et al.,
2011, 2012). Ten genetic algorithm runs were performed for each ligand giving
a total of 30 solutions. Ten genetic algorithm runs using default parameters were
performed for each ligand giving a total of 30 solutions. Docked clusters were
identiﬁed using the rms analysis implemented in GOLD. Potential hydrogen bond
interactions were visualised with PyMol 1.2.0.01 0.1 1 10 100 1000
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Fig. 3. Agonist concentrationeresponse curves for GABA, in the presence and absence
of (A) ginkgolide A, (B) ginkgolide B and (C) ginkgolide C from recombinant human r1
GABAC receptors. For each panel, the control concentrationeresponse curve (C) is
shown along with the subsequent curves obtained in the presence of 10 mM (-),
30 mM (:) and 100 mM (;) ginkgolide. Note the approximately parallel rightward
shifts in the concentrationeresponse curves, along with an inhibition of the maximum
response with an increase in ginkgolide concentration, which is characteristic of
a mixed-antagonism. The inhibition of the maximum response by ginkgolides exhibits
some degree of ‘saturation’ that is most obvious for ginkgolide C. That is, there is no
further inhibition of the maximum response (or a small change) with a further
increase in ginkgolide concentration from 30 to 100 mM. The data are ﬁtted with the
Hill equation and the average EC50, Hill coefﬁcients and normalized maximum
responses estimated from these data are shown in Table 1. Data are mean  S.E.M.
(n ¼ 4e6). Where the error bar is not obvious, it is entirely within the plotted symbol.3. Results
3.1. Functional properties of r1 GABAC receptors in X. laevis oocytes
Cytoplasmic injection of human wild-type r1 GABAC receptor
subunit cRNA into oocytes resulted in functional homomeric wild
type human r1 GABAC receptors similar to previous reports
(Kusama et al., 1993; Duke et al., 2000; Goutman and Calvo, 2004;
Carland et al., 2004a,b; 2008; Huang et al., 2006). Inward whole-0.001 0.01 0.1 1 10 100 1000 10000
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Fig. 4. Inhibition concentrationeresponse curves recorded from recombinant human
r1 GABAC receptors for (A) ginkgolide A, (B) ginkgolide B and (C) ginkgolide C, in the
presence of 0.5 mM (C), 1.2 mM (-), 3 mM (:) and 10 mM ( ) GABA. The data are ﬁtted
with the Hill equation and the average IC50 and Hill coefﬁcients estimated from these
data are shown in Table 2. Data are mean  S.E.M. (n ¼ 5e7 oocytes). Where the error
bar is not obvious, it is entirely within the plotted symbol. Note that antagonism
appears to saturate at the highest concentration of ginkgolide B.
Table 2
Parameters estimated from ﬁts of the Hill equation to inhibition curves.
GABA Ginkgolide A Ginkgolide B Ginkgolide C
IC50 (mM) nH n IC50 (mM) nH n IC50 (mM) nH n
0.5 mM 5.74  0.17 0.99  0.08 5 0.75  0.07 0.87  0.05 6 0.83  0.11 0.75  0.04 5
1.2 mM 42.3  5.76 0.82  0.07 6 2.37  0.22 0.97  0.07 7 5.39  0.59 1.04  0.14 7
3.0 mM 181.6  12.6 0.61  0.03 5 5.72  0.63 0.78  0.06 5 22.0  2.71 0.81  0.05 5
10 mM 873.7  108.4 0.73  0.04 5 129.3  21.6 0.83  0.06 7 519.8  115.1 0.83  0.05 4
IC50 is the concentration that inhibits 50% of responses, nH is the Hill coefﬁcient and n is the number of oocytes from which data was collected. Data are the mean  S.E.M.
S.H. Huang et al. / Neuropharmacology 63 (2012) 1127e1139 1131cell currents ranged from 0.2 to 3.0 mA (at a holding potential
of 60 mV) over the concentration range of 0.1e100 mMGABA. The
range of GABA EC50 and Hill coefﬁcient (nH) values were between
0.90e1.09 mM and 1.4e2.3 respectively (Table 1), consistent with
previous reports for r1 GABAC receptors. There was little if any
desensitization to GABA observed upon continued application of
GABA.Fig. 5. Use-dependent effect in the antagonism of r1 GABAC receptors by ginkgolides. A. Ex
The ginkgolides were applied 40 s prior to the ﬁrst co-application with GABA and were con
min interval. B. Histogram representing the mean data of consecutive co-applications of GA
increase in inhibition with the second application of ginkgolide B and C was not signiﬁcant. O3.2. Inhibition of GABA-mediated currents
Concentrationeresponse curves were assembled from the peak
current observed upon application of GABA or co-application of
GABA with ginkgolides A, B and C at 10 mM, 30 mM and 100 mM.
Examples of the whole-cell currents recorded from co-application
of ginkgolides are shown in Fig. 2. In each case, the ginkgolidesamples of currents recorded during repeated co-applications of GABA and ginkgolides.
tinuously present until the ﬁfth co-application. Each application was separated by a 3-
BA and ginkgolide A (n ¼ 4), ginkgolide B (n ¼ 6) and ginkgolide C (n ¼ 4). The small
verall, there was no obvious evidence for use-dependent inhibition by the ginkgolides.
Fig. 6. Recovery time from ginkgolide inhibition. Examples of current traces produced
by the co-application of 5 or 50 mM ginkgolide A, B and C during the plateau phase of
the response to 1 or 3 mM GABA. Note the faster recovery from block at higher GABA
concentrations. The recovery times (10e90% rise times) are shown in Table 3.
S.H. Huang et al. / Neuropharmacology 63 (2012) 1127e11391132produced approximately parallel rightward shifts in the GABA
concentrationeresponse curves and a decrease in the maximum
response (Fig. 3), characteristic of mixed-antagonism. The mean
values of the EC50, Hill coefﬁcient (nH) and the maximum response
obtained from ﬁtting the Hill equation are shown in Table 1. A
comparison of the EC50 values and maximum responses showed
that all GABA concentrationeresponse curves in the presence of the
ginkgolides were signiﬁcantly different from the corresponding
GABA control curves obtained from the same oocyte (Table 1).
Ginkgolide A was the least potent of the three compounds, with
a 1.9-fold, 2.3-fold and 2.5-fold increase in the EC50 value in the
presence of 10, 30 and 100 mM respectively. Ginkgolide B was the
most potent, with 3.2-fold, 4.7-fold and 7.5-fold increases in the
EC50 (for 10, 30 and 100 mM respectively). Ginkgolide C was more
similar in potency to ginkgolide B, with 3.8-fold, 6-fold and 5.3-foldTable 3
The percentage inhibition and recovery time from inhibition for co-application of ginkgo
Inhibition (%)
[GABA] 1 mM 3 mM 3 mM
[Ginkgolide] 5 mM 5 mM 50 mM
Ginkgolide A 33.8  3.4 15.9  1.6 21.4 
Ginkgolide B 55.5  3.4 35.2  6.8 54.6 
Ginkgolide C 69.9  11.3 33.3  5.0 55.7 
Data are the mean  S.E.M. (n ¼ 4e7 oocytes).increases in the EC50 (for 10, 30 and 100 mM respectively). Gink-
golide C also exhibited no apparent further increase in the EC50 or
a further decrease in the maximum response with an increase in
the concentration from 30 to 100 mM, which is suggestive of satu-
ration of inhibition. The ginkgolides had no effects when applied at
100 mM in the absence of GABA.
The inhibition curves assembled from the peak current
responses to co-application of a ﬁxed GABA concentration and
increasing concentrations of ginkgolides A, B and C are shown in
Fig. 4. The parameters obtained from ﬁtting the data with the Hill
equation are shown in Table 2. Each of the ginkgolides A, B and C
exhibited increased IC50 values when GABA concentration was
increased. For ginkgolide B, the inhibition curve in the presence of
10 mMGABA began to reach a bottom plateau of approximately 30%
of Imax in ﬁve out of the seven oocytes investigated, but it was not
possible to apply concentrations greater than 3 mM to try and
deﬁne this bottom plateau more fully. This incomplete inhibition is
a characteristic of a mechanism that exhibits saturation of inhibi-
tion (Smart and Constanti, 1986; Huang et al., 2006). Ginkgolide B
was the most potent of the three ginkgolides at all GABA concen-
trations examined. It was approximately 7.7-, 18-, 32- and 6.7-fold
more potent than ginkgolide A, and 1.1-, 2.3-, 3.8- and 4-fold more
potent than ginkgolide C at 0.5 mM, 1.2 mM, 3 mM and 10 mM GABA,
respectively. Using the IC50 values of ginkgolide B at each GABA
concentration as the control for comparison, the IC50 values for
ginkgolide A were signiﬁcantly higher in each case (P < 0.01). The
difference in the IC50 values between ginkgolides B and C at 0.5 mM
GABAwas not signiﬁcant (P¼ 0.5452), but was signiﬁcant at 1.2 mM,
3 mM and 10 mM GABA (P < 0.01).
3.3. Use-dependence effect of ginkgolides A, B and C
The use-dependence effects of ginkgolides A, B and C were
examined by repeated co-applications with GABA (1 mM) during
extended incubations of the ginkgolides (5 mM) following an initial
control GABA response (Fig. 5). After 40 s preincubation with the
ginkgolide, the set of ﬁve co-applications with GABA each showed
a similar level of inhibition: ginkgolide A, 33.2  1.4%; ginkgolide B,
61.3  1.7%; and ginkgolide C, 78.4  1.5%. This suggests that
ginkgolide A, B and C are not obviously use-dependent.
Antagonism of the ginkgolides was reversible as indicated by
full recovery of GABA responses following washout (Fig. 6). The
recovery time from inhibition (measured as the 10e90% rise
interval) was determined from the current responses obtained
when ginkgolides A, B and C were co-applied during the plateau of
the GABA-activated current (Fig. 6). The recovery times for inhibi-
tion by 5 and 50 mM ginkgolides A, B and C co-applied with 1 or
3 mM GABA are shown in Table 3. The results show that recovery of
GABA responses from 5 mM gingkolide inhibitionwas faster at 3 mM
GABA than at 1 mM, consistent with activation of the receptor in
a concentration dependent manner. Increasing the ginkgolide
concentration to 50 mM slowed the rate of recovery, suggesting the
binding of ginkgolide favoured the closed states of the receptor.lides.
Recovery time (s)
1 mM 3 mM 3 mM
5 mM 5 mM 50 mM
1.9 48.4  5.7 14.3  4.6 18.4  3.4
7.5 42.8  8.6 21.3  4.4 29.4  3.8
7.6 52.9  7.5 31.0  5.3 42.0  4.3
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Fig. 7. Macroscopic kinetic schemes ﬁtted to equilibrium concentrationeresponse
curve data. Scheme 1 represents the sequential mechanism of Amin and Weiss
(1996), which adequately describes the homomeric r1 GABAC receptor function.
This assumes ﬁve equivalent agonist binding sites but only three are required to be
occupied to activate (open) the channel pore. All subsequent kinetic schemes are
derivatives of the linear scheme, by incorporating different possible mechanisms for
antagonism by ginkgolides. These are drawn from the cyclic mixed-antagonism
mechanism described by Smart and Constanti (1986). Scheme 2 and scheme 3 both
assume that ginkgolide binds to a single site in the receptor complex. The only
difference between these schemes is that ginkgolide bound to the open state does not
allow ion conduction in scheme 3 (BA3R0), while in scheme 2 the open state remains
conducting (BA3R*). For scheme 4, the equilibrium between the fully-liganded closed
and open states is removed, which allows for the possibility that the ginkgolide binds
to a separate site in the closed state compared to the open state. In each case: R
represents the receptor complex; A represents the agonist and the subscript the
number of agonist molecules bound to the receptor; B represents the antagonist
(blocker); the asterisk denotes the open (conducting) state of the receptor; Ka is the
microscopic equilibrium constant for the agonist (GABA) and Ka0 is the microscopic
agonist equilibrium constant when ginkgolide is bound to the receptor (the macro-
scopic equilibrium constants are shown in each of the schemes); Kb0 to Kb4 are the
equilibrium constants for the ginkgolide for each state of the receptor; E is the
equilibrium constant for the opening reaction of the channel pore, where E ¼ b/a, and
b is the forward rate constant and a is the reverse rate constant; and similarly E0 is the
equilibrium constant when ginkgolide is bound.
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In an attempt to understand the mechanism of inhibition by
ginkgolides at r1 GABAC receptors, we began by ﬁtting a sequential
mechanism at equilibrium to the GABA concentrationeresponse
curves (in the absence of ginkgolides). The mechanism used
(Fig. 7, Scheme 1) is that of Amin andWeiss (1996), where there are
ﬁve equivalent agonist binding sites and three sites need to be
occupied to activate the receptor, leading to a single open state. The
ﬁts to the GABA concentrationeresponse data with this simple
mechanism produced a good description of the data. However, the
parameters obtained had large standard errors and there was
strong dependency between the agonist equilibrium dissociation
constant, Ka, and the channel opening equilibrium, E, suggesting
the data is not sufﬁcient to precisely deﬁne each of the parameters.
When the value for E was ﬁxed to 11 (the value obtained by Amin
and Weiss, 1996), the ﬁts were visually indistinguishable to the
free ﬁts and the value for Ka was more reasonably determined as
3.22 0.04 mM (value SE). This is of a similar order to the value of
1.4 mM obtained by Amin and Weiss (1996) and is consistent with
the EC50 for GABA of 0.8 mM compared to 1.2 mM reported here. For
all subsequent mechanisms ﬁt to the data that incorporated inhi-
bition by ginkgolides, the values for Ka and E were ﬁxed to 3.2 mM
and 11 (respectively), so as to provide better precision in estimating
the other parameters.
Initially, a cyclic allosteric mechanism (Fig. 7, scheme 2)
similar to that of Smart and Constanti (1986) was ﬁt to the data.
This scheme assumes a single binding site on the receptor
complex that has an allosteric effect on all rate constants in the
reaction mechanism. The scheme was ﬁtted to the data allowing
the agonist equilibrium constant, Ka, to be related to the equi-
librium constant in the presence of ginkgolide, Ka0 by a constant
ratio, R ¼ Ka/Ka0. Similarly, the opening equilibrium constants E
and E0 were related by the ratio, S ¼ E/E0. This scheme ﬁtted all
three of the data sets well, describing both the rightward shift in
the curves with increasing ginkgolide concentration and the
decrease in the maximum response (Fig. 8AeC). The values
obtained from the ﬁts are shown in Table 4. As a test of the
mechanism, the parameters obtained from the ﬁt were used to
predict the inhibition curves (Fig. 8DeF). The predicted inhibition
curves exhibit rightward-shifts with increased GABA concentra-
tion and saturation of inhibition, where the bottom of the curves
does not show complete inhibition for 3 and 10 mM GABA.
Saturation of inhibition is a consequence of the allosteric mech-
anism, since the binding of antagonist alters the opening reaction
equilibrium (E0), while the total number of receptors available to
open remains the same. These predicted curves do not
completely describe the experimental inhibition curves, as
saturation was not generally observed except for ginkgolide B in
the presence of 10 mM GABA.
If scheme 2 is modiﬁed so that ginkgolide bound to the open
state of the receptor results in a non-conducting state (denoted as
BA3R0 in scheme 3), then saturation of inhibition no longer occurs.
As a result the predicted inhibition curves (Fig. 9DeF) are more
similar to the experimental data, however the ﬁt of this mechanism
(scheme 3, Fig. 7) results in a much poorer ﬁt to the top of the
concentrationeresponse curves (Fig. 9AeC) and there was strong
dependency between the parameters Kb4, R and S. As a result, some
of the parameters (particularly for ginkgolide B) could not be
adequately deﬁned; they had large standard errors and there was
an increase in standard deviation of the residuals for the ﬁt
compared to scheme 2 (Table 4).
In an attempt to ﬁnd a mechanism that is able to ﬁt the
concentrationeresponse curves and predict the inhibition curves,
scheme 2wasmodiﬁed to remove the channel opening equilibriumfor the ginkgolide bound receptor (between BA3R and BA3R*; E0) to
give scheme 4 (Fig. 7). This effectively means that ginkgolide is
binding at two separate sites. This resulted in almost identical ﬁts
as scheme 2 for the concentrationeresponse curves and still pre-
dicted inhibition curves with saturation. Scheme 4 is therefore
AB
C
D
E
F
Fig. 8. Results from scheme 2 (Fig. 7). Equilibrium concentrationeresponse curves ﬁtted with scheme 2 for (A) ginkgolide A, (B) ginkgolide B and (C) ginkgolide C. In each case, the
parameters for the response to GABA alonewere ﬁxed (Ka¼ 3.2 mMand E¼ 11) to improve the precision on the remaining parameters estimated. All parameters for the ﬁt were shared
across the data sets for each ginkgolidewith the exception of the concentration of the ginkgolide (0,10, 30 and 100 mM). The ﬁt of scheme 2 describeswell themixed-antagonism of the
data sets for ginkgolide A, B and C. PanelsDeF show the predicted inhibition curves generatedwith the parameters obtained from the ﬁt to the concentrationeresponse curves exhibit
saturation of inhibition, where the bottom of the curve reaches a plateau rather than a full inhibition of the response. The plotted symbols in each panel are as for Fig. 3; equilibrium
concentrationeresponse data for GABA in the absence of ginkgolide (C) and in the presence of 10 mM (-), 30 mM (:) and 100 mM (;) ginkgolide.
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Other more complicated schemes introduced further parameters,
which meant there was increased dependency between the
parameters and they could not be adequately deﬁned.Table 4
Parameters estimated from the ﬁt of schemes 2, 3 and 4.
Sy.x Fitted parameters
Kb4 (mM) R S
Scheme 2 GA 3.64 19.7  3.9 0.56  0.03 2.6
GB 4.55 35.2  5.4 0.39  0.02 8.6
GC 3.61 6.1  1.1 0.38  0.02 5.3
Scheme 3 GA 4.46 611  89 0.06  0.05 0.0
GB 5.65 1.7  1011  2.3  1017 0.25  0.01 1.0
GC 7.86 316  132 0.10  0.04 3.2
Scheme 4 GA 3.64 19.7  3.9 0.55  0.03 e
GB 4.55 35.2  5.4 0.39  0.02 e
GC 3.61 6.1  1.1 0.38  0.02 e
Ka was ﬁxed to 3.2 mM and E was ﬁxed to 11. Ka0 and Kb0 was calculated from R ¼ Ka/Ka
Sy.x is the standard deviation of the residuals from the non-linear regression. GA, ginkgo3.5. Modelling and docking
Amino acid sequence alignment of the r1 GABA subunit with the
GLIC sequence showed a good conservation within the M2 poreCalculated parameters
Ka0 (mM) E0 Kb3 (mM) Kb0 (mM)
 0.2 5.7 4.3 7.7 1.3
 0.6 8.3 1.3 4.1 0.2
 0.2 8.4 2.1 1.1 0.1
9  0.22 53.3 122 6789 1.5
 1010  1.4  1016 12.9 1  109 16.7 0.3
 4.1 31.2 3.4 98.7 0.1
5.7 e 7.7  1.4 1.3
8.3 e 4.1  0.5 0.2
8.4 e 1.1  0.2 0.1
0 ¼ Kb0/Kb1 ¼ Kb1/Kb2 ¼ Kb2/Kb3; E0 and Kb3 were calculated from S ¼ E/E0 ¼ Kb4/Kb3.
lide A; GB, ginkgolide B; GC, ginkgolide C. Values are SE.
AB
C
D
E
F
Fig. 9. Results from scheme 3 (Fig. 7). Equilibrium concentrationeresponse curves ﬁtted with scheme 3 for (A) ginkgolide A, (B) ginkgolide B and (C) ginkgolide C. As for scheme 2,
the parameters for the response to GABA alone were ﬁxed (Ka ¼ 3.2 mM and E ¼ 11) and all other parameters were shared across the data sets for each ginkgolide with the exception
of the concentration of the ginkgolide (0, 10, 30 and 100 mM). The ﬁt with scheme 2 was noticeably worse, with the curve failing to follow the data points at the top of the
concentrationeresponse curve and consequently an increase in the standard deviation of the residuals for the ﬁt. The predicted inhibition curves (panels DeF) exhibit complete
inhibition at each of the GABA concentrations (numbers indicate 0.5, 1.2, 3.0 and 10 mM GABA). The plotted symbols in each panel are as for Fig. 3; equilibrium concen-
trationeresponse data for GABA in the absence of ginkgolide (C) and in the presence of 10 mM (-), 30 mM (:) and 100 mM (;) ginkgolide.
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GABAC receptorhomologymodel and the3EAMtemplate of theGLIC
receptor showed that the homology model was very similar within
the transmembrane region (Fig.10). GinkgolidesA, B andCdocked in
the pore between 20 and 10 residues. The docked poses fell into two
major groups, either orientated along the axis of the pore (Fig. 11A
andB) or,with the ligandperpendicular to the pore axis (Fig.11Dand
E). A series of hydrogen bonds were predicted for all the ligands
tested. In the majority (19/23) of the predicted H-bonds, this inter-
action was with the C3 or C10 hydroxyl of ginkgolides, A, B and C
ligand. The unique C7 hydroxyl in ginkgolide C was predicted to
interact in two of the poses, but the C1 hydroxyl in ginkgolide B and
ginkgolide C did not account for any of the interactions.
4. Discussion
4.1. Ginkgolide antagonism
We show here that ginkgolide A, B and C are mixed antago-
nists at human recombinant r1 GABAC receptors, exhibitpotencies that are dependent on concentration of GABA, and
require channel activation to dissociate from the receptor. The
GABA concentrationeresponse curves show approximate parallel
shifts in the presence of ginkgolides, suggestive of a competitive
effect. The noncompetitive effect is illustrated by the decrease in
the maximum response of the GABA concentrationeresponse
curves in the presence of the ginkgolides. Apparent competitive
antagonism is evident as IC50 values are clearly dependent on
GABA concentrations. The ginkgolides are most potent at the
lowest GABA concentration tested (0.5 mM) and the potency
decreases as GABA concentrations increase (1.2 and 3 mM). A true
noncompetitive antagonist would produce a constant IC50 value
regardless of the agonist concentrations. The variation in
potency with different GABA concentrations shows that the
ginkgolides are neither classical competitive nor classical
noncompetitive antagonists, conﬁrming our results from GABA
concentrationeresponse curves in the presence of increasing
antagonist concentrations. These results are indicative of the
ginkgolides exhibiting mixed-type noncompetitive antagonism at
r1 GABAC receptors.
Fig. 10. A comparison of the channel from 3EAM and the r1 GABAC receptor homology
model used in this study. The proﬁle is plotted as the average pore diameter for the
whole pentamer (solid line, r1 GABAC receptor homology model; dotted line, 3EAM).
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noncompetitive antagonism at the r1 GABAC receptors (Huang
et al., 2006). Antagonism by PTX at GABAC receptors has been
shown to comprise both competitive and noncompetitive compo-
nents (Woodward et al., 1992; Qian and Dowling, 1994; Wang et al.,
1995; Qian et al., 2005; Carland et al., 2008). The competitive
component could be removed from PTX antagonism at the r1
GABAC receptor by substitution of the proline residue at position 20
with the homologous residue of the GABAA receptor a1 and b2
subunits and the glycine receptor a1 subunit at the saturated
concentration of GABA but not at the EC50 of GABA (Wang et al.,
1995; Carland et al., 2008). As PTX does not compete at the GABA
binding site (Ramanjaneyulu and Ticku, 1984), the competitive
antagonism of PTX is only apparent. This suggests that PTX acts as
an allosteric inhibitor and alters the equilibrium for agonist binding
and channel opening, consistent with different afﬁnity of PTX for
the receptor in the open and closed states from kinetic modelling of
the GABAC receptor (Qian et al., 2005).
Residues in30 to 20 positions contributes to the GABAC receptor
pore (Filippova et al., 2004) and play a major role in channel gating
in the Cys-loop receptors (Barry and Lynch, 2005; Miller and Smart,
2010). The residue at position 20 has been shown to inﬂuence
response kinetics, ion permeability, selectivity and conductance of
the GABAC receptors (Qian et al., 1999; Wotring et al., 2003, 2008;
Carland et al., 2004a,b; Filippova et al., 2004; Zhu et al., 2007).
Ginkgolide B has been shown by molecular modelling to be struc-
turally similar to PTX (Ivic et al., 2003) and the ginkgolides only
differ from one another in the hydroxyl substituents. In analogy to
PTX, we suggest the ginkgolides also act as allosteric inhibitors
altering the equilibrium for agonist binding and channel opening.4.2. Use-dependence action of ginkgolides
We also examined the use-dependent actions of the ginkgolides
on r1 GABAC receptors using procedures described by Goutman and
Calvo (2004) and Huang et al. (2006). Multiple co-applications of
ginkgolides with GABA, in the continued presence of ginkgolide,
exhibited no change in the level of inhibition (Fig. 5A and B). Thus,
there is no obvious use-dependence in the antagonism of the
ginkgolides. However, there is a clear dependency of the recovery
time from the ginkgolide block on the agonist concentration
(Fig. 6).
The association rate of GABA is four orders of magnitude
slower than diffusion at the r1 GABAC receptors indicating GABA
has restricted access to its binding site at this receptor (Chang
and Weiss, 1999). They also showed that GABA dissociates at
two rates and proposed two mechanisms for dissociation of
GABA. The faster rate corresponds to the true microscopic
dissociation rate of agonist dissociation from the GABA binding
site. The slower rate occurs because pore opening detains GABA
release. That is GABA dissociation is inhibited during receptor
gating. This helps to explain why the dissociation rate of PTX is
faster than that of GABA at the GABAC receptors in acutely iso-
lated catﬁsh cone horizontal cells (Dong and Werblin, 1996). In
analogy to PTX, we suggest that the lack of use-dependent
antagonism by ginkgolides at the r1 GABAC receptor is because
its dissociation rate is much faster than GABA. The slow associ-
ation rate of GABA and a fast dissociation rate for ginkgolides
could also account for the observed time course of recovery from
ginkgolide block (Fig. 6) that is dependent on the GABA
concentration.4.3. Kinetic models of ginkgolide antagonism
Mixed-antagonism by PTX was ﬁrst shown at lobster muscle
GABA receptors (Constanti, 1978; Smart and Constanti, 1986). An
allosteric model was developed where PTX interacts with the
receptor complex in both channel closed and channel open states,
and modulated the equilibrium constants between the receptor
states (Smart and Constanti, 1986). This scheme accounted for the
mixed-antagonism and the saturation of inhibition observed for
PTX.
To explain the mechanism of action of ginkgolides at r1 GABAC
receptors, the concentrationeresponse curves in the presence and
absence of ginkgolides were ﬁt with several kinetic schemes. All
schemes assumed that there were ﬁve equivalent GABA binding
sites on the receptor complex and that three binding sites needed
to be occupied in order to activate the receptor with a single open
state (Amin andWeiss, 1996). The datawere best ﬁt with schemes 2
and 4, based upon the cyclic kinetic scheme of Smart and Constanti
(1986). Scheme 4 allows for the possibility that the ginkgolide binds
to a different site in the closed and open states of the receptor. Both
schemes 2 and 4 ﬁtted the data equally well and predict a higher
afﬁnity for ginkgolides in the closed states. This is likely to account
for the recovery from inhibition observed in Fig. 6 (rise times
shown in Table 3).
In support of scheme 4, a kinetic model of the r1 GABAC
receptors indicated that the afﬁnity of PTX was higher for the
receptor in the closed than the open state (Qian et al., 2005). There
is some evidence that PTX binds to a different site in the closed and
open state of the receptor. PTX has been shown to protect the
residue mutated to cysteine at positions 20 and 170 of the GABAA a1
subunit from cross-linking with the sulfhydryl-reactive probes
derived from the GABAA noncompetitive blockers (Perret et al.,
1999). PTX has been proposed to bind to a use-dependent site
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application of GABAwith PTX generated an onset current transient
from GABAC receptor in acutely isolated catﬁsh cone horizontal
cells not pre-incubated with PTX but not in the cells pre-incubated
with PTX (Dong and Werblin, 1996). The butyrolactone antagonist
a-isopropyl-a-methyl-g-butyrolactone (a-IMGBL) abolished the
use-dependence part of the PTX block but had no signiﬁcant effect
on PTX block of GABA peak current at the GABAA receptors in
dissociated rat hippocampal neurons (Yoon et al., 1993). PTX has
been shown to bind to the closed and the GABA-bound open states
of the GABAA receptors (Newland and Cull-Candy, 1992; Dillon
et al., 1995). In parallel to PTX, we suggest that the ginkgolides
may also bind to different sites of the r1 GABAC receptor in the
closed and open states, and that they bind with higher afﬁnity to
the receptor in the closed state.
4.4. Structure activity relationship of the ginkgolides
At r1 GABAC receptors, the ginkgolides and PTX showed
a signiﬁcant decrease in potency with increase concentration of
GABA (Table 2; Huang et al., 2006). Ginkgolide A is signiﬁcantly less
potent than ginkgolides B and C (Table 2) and much less potent
than PTX (Huang et al., 2006). The variation between the potency of
the ginkgolide A and ginkgolides B and C may be explained, at least
in part, in terms of their structural differences. In the X-ray struc-
ture of ginkgolides B and C, there is an intramolecular hydrogen
bond between the C1 and C10 hydroxyls (Fig. 1) (Dupont et al.,
1986; Sbit et al., 1987; Zhao et al., 2002). The hydrogen atom of
the C1 hydroxyl forming a hydrogen bond to the oxygen atom of the
C10 hydroxyl is evident in the X-ray structure of ginkgolide C (ZhaoFig. 11. Examples of the two main docked poses for ginkgolide B in the r1 GABAC receptor
residues P20 and T60 , all others have been removed for clarity. For ginkgolide A, ginkgolide
ginkgolide B (the most potent ligand) is shown. Panels A and D show the docked pose as seen
are the same poses viewed from the side. Ginkgolide B is shown in stick representation. Pane
the rotation of the ginkgolide B ligand.et al., 2002). The 1H NMR resonances conﬁrmed the presence of the
intramolecular hydrogen bonding and also assigned the hydrogen
bond donor role to the C1 hydroxyl and the acceptor role to the C10
hydroxyl in ginkgolides B and C (van Beek and Lankhorst, 1996;
Bernet and Vasella, 2000).
The intramolecular hydrogen bonding between the C1 and C10
hydroxyl provides the rationales for the size of ginkgolide B (20
carbon atoms) being not so different when it was overlayed on PTX
(15 carbon atoms) (Ivic et al., 2003). With the absence of the C1
hydroxyl, there is no intramolecular hydrogen bond to inﬂuence
the structural conformation of ginkgolide A. All conformers of
ginkgolide A have a larger distance-spanning lactones C and F than
those of ginkgolide B (Ivic et al., 2003). This may account for the
potency of ginkgolide A being distinct from that of ginkgolides B
and C at r1 GABAC receptors. The additional hydroxyl at C7 in
ginkgolide C could hinder hydrophobic interaction of the t-butyl
side chain to the pore residue, and may account for the lower
potency of ginkgolide C compared to that of ginkgolide B.
4.5. Allosteric mechanism of action versus docking to pore residues
In ginkgolides B and C, the C1 hydroxyl acts a hydrogen bond
donor in the intramolecular hydrogen bonding with the C10
hydroxyl (Dupont et al., 1986; Sbit et al., 1987; van Beek and
Lankhorst, 1996; Bernet and Vasella, 2000; Zhao et al., 2002). This
explains why the C1 hydroxyl was not predicted to hydrogen bond
in any of the docking poses. Docking of the ginkgolides close to the
proline residue at position 20 suggests that the binding site of the
ginkgolides may overlap with the PTX binding site. The residue at
position 20 has been suggested by site directed mutagenesis andhomology model. M2 helices are shown as ribbons, and apart from the side chains of
B (GB) and ginkgolide C, the orientations of the ligands were the same, and so only
looking from the extracellular domain, down through the receptor pore. Panels B and E
l C is in the same orientation as panel A, but shows an overlay of two poses, highlighting
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stabilize the binding of PTX to threonine at position 60 at the
homology model of GABAA, GABAC and GABARDL receptors, and
mutation of the residues at this position signiﬁcantly affects the
receptor sensitivity to PTX (Xu et al., 1995; Gurley et al., 1995; Perret
et al., 1999; Zhorov and Bregestovski, 2000; Chen et al., 2006;
Erkkila et al., 2008; Thompson et al., 2011, 2012). However, kinetic
studies have shown that PTX acts by allosteric stabilization of GABA
bound desensitized state(s) of the GABAA receptors and not by
directly occluding the pore (Twyman et al., 1989; Newland and
Cull-Candy, 1992; Ramakrishnan and Hess, 2005; Krishek et al.,
1996; Korshoej et al., 2010).
Mutations in the pore domain have been shown to affect
picrotoxin afﬁnity and gating by GABA, and also uncouple gating
and desensitization of the GABAA receptor (Buhr et al., 2001;
Scheller and Forman, 2002). Thus, gating/desensitization being
uncoupled to the pore domain could account for the change in PTX
sensitivity of the receptors in response to mutation of the pore
residues. Proline 20 may constitute a part of the structure that
couples gating and desensitization of GABAC receptors as it has
been shown to inﬂuence response kinetics, ion permeability,
selectivity and conductance of the GABAC receptors (Qian et al.,
1999; Wotring et al., 2003, 2008; Carland et al., 2004a,b;
Filippova et al., 2004; Zhu et al., 2007). As in the GLIC X-ray
structure, the conformation in the homology model is likely to
represent the open conformation. However, this may not be
adequately represented in the conformation that binds the gink-
golides. This could explain the conﬂicting predictions of the
molecular modelling and that of the ﬁtted kinetic schemes that
suggest the ginkgolides do not bind in the channel pore. Until we
have a high-resolution structure of the GABA receptor, we must be
cautious in the interpretation of the docking data, especially as the
r1 GABAC receptor has a proline residue at the 20 position, which is
not present in the template and has the potential to signiﬁcantly
inﬂuence the receptor structure. Cisetrans isomerization of proline
has been shown to act as a switch in the opening of the pore of the
5-HT3 receptors (Lummis et al., 2005).
In conclusion, the ginkgolides exert mixed-type noncompetitive
antagonism at r1 GABAC receptors. We suggest that this is
explained by an allosteric inhibition mechanism. Kinetic modelling
predicts that ginkgolides exhibit saturation of antagonism at high
concentrations of GABA, but this was only partially observed for
ginkgolide B. It also suggests that there may be different binding
sites in the closed and open states of the receptor, with a higher
afﬁnity for the receptor in the closed state.
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